The stock of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) is a huge mover today! The stock increased 3.77% or $0.2 during the last trading session, hitting $5.51. About 2.44M shares traded hands. Synergy Pharmaceuticals Inc (NASDAQ:SGYP) has risen 56.18% since February 26, 2016 and is uptrending. It has outperformed by 45.75% the S&P500.
The move comes after 5 months positive chart setup for the $935.88M company. It was reported on Oct, 1 by Barchart.com. We have $7.27 PT which if reached, will make NASDAQ:SGYP worth $299.48 million more.
Analysts await Synergy Pharmaceuticals Inc (NASDAQ:SGYP) to report earnings on November, 14. They expect $-0.22 EPS, up 4.35% or $0.01 from last year’s $-0.23 per share. After $-0.23 actual EPS reported by Synergy Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -4.35% EPS growth.
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) Ratings Coverage
Out of 5 analysts covering Synergy Pharmaceuticals (NASDAQ:SGYP), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. Synergy Pharmaceuticals has been the topic of 8 analyst reports since August 25, 2015 according to StockzIntelligence Inc. Roth Capital reinitiated it with “” rating and $9.50 target price in Thursday, October 29 report. The firm has “Neutral” rating given on Wednesday, March 16 by Citigroup. The firm has “Buy” rating given on Thursday, October 29 by TH Capital. The firm has “Buy” rating given on Tuesday, August 25 by BTIG Research. The stock of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) has “Buy” rating given on Monday, March 21 by Rodman & Renshaw. The stock has “Buy” rating given by Rodman & Renshaw on Monday, May 9. The firm earned “Buy” rating on Thursday, October 1 by H.C. Wainwright. The stock has “Neutral” rating given by Citigroup on Friday, December 18.
According to Zacks Investment Research, “Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. Its lead drug candidate plecanatide is a guanylyl cyclase C receptor agonist, to treat GI disorders, primarily chronic constipation and constipation-predominant- irritable bowel syndrome. It is also engaged in developing receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals, Inc. is headquartered in New York, New York.”
Insitutional Activity: The institutional sentiment increased to 1.61 in 2016 Q2. Its up 0.55, from 1.06 in 2016Q1. The ratio increased, as 16 funds sold all Synergy Pharmaceuticals Inc shares owned while 28 reduced positions. 25 funds bought stakes while 46 increased positions. They now own 99.69 million shares or 58.37% more from 62.94 million shares in 2016Q1.
Susquehanna Int Gp Limited Liability Partnership accumulated 0% or 469,148 shares. Deutsche Financial Bank Ag holds 866,716 shares or 0% of its portfolio. The United Kingdom-based Cheyne Cap Mgmt (Uk) Llp has invested 0.2% in Synergy Pharmaceuticals Inc (NASDAQ:SGYP). Moreover, Ladenburg Thalmann Svcs Inc has 0% invested in Synergy Pharmaceuticals Inc (NASDAQ:SGYP) for 31,000 shares. Creative Planning holds 117,436 shares or 0% of its portfolio. Moreover, Parametric Portfolio Associates Ltd Liability has 0% invested in Synergy Pharmaceuticals Inc (NASDAQ:SGYP) for 66,568 shares. Tower Capital Ltd Liability Corporation (Trc) reported 139 shares or 0% of all its holdings. Blackrock Advsrs Lc last reported 0% of its portfolio in the stock. Balyasny Asset Mngmt Limited Liability Corporation owns 62,988 shares or 0% of their US portfolio. Credit Suisse Ag has 195,140 shares for 0% of their US portfolio. Bnp Paribas Arbitrage owns 7,090 shares or 0% of their US portfolio. Blackrock Institutional Na holds 0% of its portfolio in Synergy Pharmaceuticals Inc (NASDAQ:SGYP) for 3.69M shares. Millennium Mngmt Llc has invested 0.01% of its portfolio in Synergy Pharmaceuticals Inc (NASDAQ:SGYP). Strategic Investment Mgmt Lc last reported 30,381 shares in the company. Citigroup Incorporated owns 627,134 shares or 0% of their US portfolio.
Insider Transactions: Since September 16, 2016, the stock had 0 insider buys, and 2 sales for $19.50 million net activity. 2,518 shares were sold by BRANCACCIO JOHN P, worth $14,504 on Monday, September 19. The insider PAULSON & CO. INC. sold $19.49M.
Another recent and important Synergy Pharmaceuticals Inc (NASDAQ:SGYP) news was published by Businesswire.com which published an article titled: “Synergy Pharmaceuticals Announces New Plecanatide Data Presentations at …” on September 28, 2016.
SGYP Company Profile
Synergy Pharmaceuticals Inc. (Synergy), incorporated on February 11, 1992, is a biopharmaceutical firm focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s GI platform includes two lead product candidates: plecanatide and dolcanatide. It is engaged in the discovery, research and development involving uroguanylin analogs for the treatment of functional GI disorders and inflammatory bowel disease.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.